Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05284747 · ClinicalTrials.gov registry record · Phase 4
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
A Phase 4 study of Stroke and Cardiovascular Disease, sponsored by Amgen.
- Active
- Registry status
- Phase 4
- Development phase
- 6,019
- Enrollment target
- 20
- Study locations
NCT05284747: Active Phase 4 study of Stroke and Cardiovascular Disease, sponsored by Amgen.
NCT05284747 is a Phase 4 study of Stroke and Cardiovascular Disease that is active but no longer recruiting, run by Amgen. The registered enrollment target is 6,019 participants, below the 12,003-participant average among 454 other Stroke trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05284747, a Phase 4 study of Stroke and Cardiovascular Disease, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 6,019 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).
Conditions Studied
Interventions
- DRUG Evolocumab
- DRUG Routine Lipid Management
Study Locations (20)
Florida
- Excel Medical Clinical Trials - Boca Raton
- Clearwater Cardiovascular Consultants - Clearwater
- University of Florida at Gainesville - Gainesville
- University of Florida and Shands Hospital - Jacksonville
- AdventHealth Orlando - Orlando
- Cardiology Partners Clinical Research Institute - Palm Beach Gardens
California
- John Muir Health and Cardiovascular Institute - Concord
- VA Greater Los Angeles Healthcare System - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California-Irvine - Orange
Alabama
- University of Alabama at Birmingham - Birmingham
- Eastern Shore Research Institute - Fairhope
- Heart Center Research LLC - Huntsville
Arizona
- Northern Arizona Healthcare Corporation Cardiovascular Institute - Flagstaff
- Scottsdale Healthcare at Shea - HonorHealth - Scottsdale
- Pima Heart and Vascular Clinical Research - Tucson
Connecticut
- Bridgeport Hospital - Bridgeport
- Hartford Hospital - Hartford
- Cardiology Associates of Fairfield County PC - Stamford
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,019 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2027-05-29 |
| Phase | Phase 4 |
What the registry record for NCT05284747 still lists
NCT05284747 is an interventional study that assigns participants to a tested intervention. Its 6,019 participants enrollment target places it among the larger protocols in the corpus, below the 12,003-participant average among 454 other Stroke trials with a reported enrollment target (50% lower).
The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Evolocumab is the first listed.
NCT05284747 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05284747 about?
NCT05284747 is a clinical study titled "EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction". The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause d...
What is the current status of trial NCT05284747?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 6,019 participants. The study started on 2022-10-26. Estimated completion is 2027-05-29.
What conditions does trial NCT05284747 study?
This clinical trial studies the following conditions: Stroke, Cardiovascular Disease, Myocardial Infarction, Coronary Revascularization.
What interventions are being tested in trial NCT05284747?
The interventions under investigation include: Evolocumab (DRUG), Routine Lipid Management (DRUG).
Who is sponsoring clinical trial NCT05284747?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05284747 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05284747's enrollment target sits among peer trials
6,019 11th of 454 higher than 444 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
International Care Bundle Evaluation in Cerebral Hemorrhage Research
RECRUITING · Phase 4
-
Xeomin® and Gait Related Mobility After Stroke
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
COMPLETED · Phase 4
-
Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05884190 · 6,030 participants · NA
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI